Objectives: An attempt has been made to demonstrate the value of the immunocytochemical assay of Ki67 antigen expression in blast cells in children with acute lymphoblastic leukaemia (ALL) before initiation of treatment and its correlation with early treatment failure. Methods: Bone marrow specimens were obtained before treatment from children hospitalised in the years 1997–2000. A total of 60 children diagnosed with ALL have been examined. Immunocytochemical staining for Ki67 expression was based on the ABC technique. Results: Out of 45 children assigned to the low risk group, the presence of Ki67 Ag was demonstrated in 31 cases (68.8%). Out of 15 patients in the high risk group, Ki67 Ag expression in blast cells was positive in 8 children (53.3%). The fraction of immunopositive cells in these groups ranged from 19.8 to 81.3% compared to 5% in the control group. Early treatment failure was observed in both groups and these were closely related to the lack of Ki67 expression observed at the beginning of treatment. Conclusion: The results indicate a possible connection between the Ki67 immunonegative blast pattern and early leukaemia progression. It may also justify routine determination of Ki67 Ag before the treatment of ALL is initiated.

Keywords:
Ki67 antigen, Leukaemia, Treatment failure
1.
Amylon M, Murphy S, Pullen J: Treatment of lymphoid malignancies according to immune phenotype: Preliminary results in T-cell disease. Proc ASCO 1988;7:225.
2.
Rivera GK, Mauer AM: Controversies in the management of childhood acute lymphoblastic leukaemia: Treatment intensification, CNS leukaemia and prognostic factors. Semin Hematol 1987;24:12–26.
3.
Tsurusawa M, Ito M, Zha Z, Kawai S, Takasaki Y, Fujimoto T: Cell-cycle-associated expression of proliferating cell nuclear antigen and Ki67 reactive antigen of bone marrow blast cells in childhood acute leukaemia. Leukaemia 1992;6:669–674.
4.
Ball LM, Lannon CL, Yhap M: PCNA bearing structures are retained in apoptotic phase of childhood ALL cell cycle. Adv Exp Med Biol 1999;457:289–296.
5.
Kawahira K: Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases. Arch Dermatol Res 1999;291:413–418.
6.
Shi SR, Cote RJ, Taylor CR: Antigen retrieval immunohistochemistry: Past, present and future. J Histochem Cytochem 1997;45:327–343.
7.
Shi SR, Cote RJ, Young LL, Taylor CR: Antigen retrieval immunohistochemistry: Practice and development. J Histotechnol1997;20:145–152.
8.
Pileri SA, Roncador G, Ceccarelli C: Antigen retrieval techniques in immunohistochemistry: Comparison of different methods. J Pathol 1997;183:116–123.
9.
Crist WM, Grosse CE, Pullen J: Immunologic markers in childhood acute lymphoblastic leukaemia. Semin Oncol 1985;12:105–112.
10.
Nowicki M, Miśkowiak B, Konwerska A: Expression of CD79a antigen in acute lymphoblastic leukemias in children. Folia Histochem Cytobiol 1999;37:149–150.
11.
National Committee for Clinical Laboratory Standards: Internal quality control testing: Principles and definitions; approved guideline. Villanova, 1991.
12.
Elias JM, Gown AM, Nakamura RM: Special report: Quality control in immunohistochemistry. Am J Clin Pathol 1989;92:836–843.
13.
Gore SD, Weng LJ, Burke PJ: Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation. Leukemia 1994;8:1854–1863.
14.
Lopez F, Belloc F, Lacombe F: The labellling of proliferating cells by Ki67 and MIB-1 antibodies depends on the binding of a nuclear protein to DNA. Exp Cell Res 1994;210:145–153.
15.
Glasova M, Konikova E, Kusenda J, Babusikova O: Flow cytometric detection of some activation and proliferation markers in human hematopoietic cell lines. Neoplasma 1996;43:381–388.
16.
Glasova M, Konikova E, Kusenda J, Babusikova O: Evaluation of different fixation-permeabilization methods for simultaneous detection of surface, cytoplasmic markers and DNA analysis by flow cytometry in some human hematopoietic cell lines. Neoplasma 1995;42:337–346.
17.
Muller P, Hempel D, Oruzio D, Ehnle S, Kolloch K, Schlimok G: Sequential immunotyping and genotyping of tumor cells in bone marrow of cancer patients: A model study. Cytometry 1998;33:492–497.
18.
Bobrow M: Catalysed reporter deposition, a novel method of signal implification: Application to immunoassays. J Immunol Meth 1989;125:279.
19.
Tsurusawa M, Fujimoto T: Cell cycle progression and phenotypic modification of Ki67 antigen-negative G1- and G2-phase cells in phorbol ester-treated Molt-4 human leukemia cells. Cytometry 1995;20:146–153.
20.
Tsurusawa M, Aoyama M, Saeki K, Fujimoto T: Cell cycle kinetics in childhood acute leukemia studied with in vitro bromodeoxyuridine labeling, Ki67-reactivity, and flow cytometry. Leukemia 1995;9:1921–1925.
21.
Lacombe F, Belloc F: Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol Cell Ther 1996;38:495–504.
22.
Pyesmany AF, Ball LM, Yhap M: Proliferation and apoptosis does not affect presenting white cell count in childhood ALL. Adv Exp Med Biol 1999;457:305–312.
23.
Pyesmany AF, Ball LM, Yhap M: Apoptotic fraction in childhood ALL assessed by DNA in situ labeling is ploidy independent. Adv Exp Med Biol 1999;457:281–287.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.